Pfizer
Astrid Ruefli-Brasse has had a successful career in the field of biotechnology and pharmaceuticals. Astrid is currently working at Pfizer as the Vice President of Tumor Biology. Prior to joining Pfizer, they held leadership roles at 23andMe, where they served as the Vice President and Head of Discovery and Translational Research, as well as the Director of Drug Discovery. Before that, they worked at Roche as a Senior Group Leader and Vice Director. Earlier in their career, Astrid was a Principal Scientist at Amgen, where they led a research lab and was involved in the development of small molecule and protein-based therapeutics for oncology. Astrid also served as a Post-doc at Genentech. Astrid's work experience spans over two decades and they have demonstrated expertise in various aspects of cancer research and drug discovery.
Astrid Ruefli-Brasse earned a Bachelor of Arts degree in Biology from the University of Rochester in 1993. Astrid went on to complete their PhD in Cell Biology/Cancer Immunology at the University of Melbourne from 1998 to 2002.
This person is not in any teams
This person is not in any offices
Pfizer
615 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.